Fennec Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 14, 2025

Core Points - Fennec Pharmaceuticals Inc. will release its Q2 2025 financial results on August 14, 2025, before U.S. market opening [1] - A conference call and webcast will be held on the same day to discuss financial and business results [1][2] Company Overview - Fennec Pharmaceuticals is focused on protecting cancer patients from cisplatin-induced hearing loss through its product PEDMARK, which received FDA approval in September 2022 and European Commission approval in June 2023 [3] - The product is marketed as PEDMARQSI in the U.K. and has been commercialized in the U.K. and Germany following an exclusive licensing agreement with Norgine Pharmaceuticals [4] - PEDMARK has Orphan Drug Exclusivity in the U.S. and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, providing significant market protection [5]